Skip to main content
. Author manuscript; available in PMC: 2019 Sep 15.
Published in final edited form as: Clin Cancer Res. 2018 May 30;24(18):4416–4428. doi: 10.1158/1078-0432.CCR-17-3649

Figure 2. Impact of checkpoint blockade exposure prior to TIL ACT on response and survival.

Figure 2

(A) Best overall response stratified by checkpoint blockade therapy (anti-CTLA4 and/or anti-PD1) prior to TIL ACT (n=74). (B) On the left side, overall survival of checkpoint naïve patients prior to TIL ACT (black line) and anti-CTLA4 exposed patients prior to TIL (pink line). On the right side, multivariable analysis including 8 parameters. (C) Spider plot illustrating tumor regression through time after TIL infusion for checkpoint naïve patients prior to TIL ACT (black line) and anti-CTLA4 exposed patients prior to TIL (pink line). Only responders to TIL ACT are represented.